WMSA
ESPR

Weiss Multi-Strategy Advisers’s Esperion Therapeutics ESPR Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-17,400
Closed -$1.42M – 423
2015
Q2 		$1.42M Buy
17,400
+7,400
+74% +$724K 0.06% 291
2015
Q1 		$926K Sell
10,000
-50,000
-83% -$3.23M 0.04% 326
2014
Q4 		$2.43M Buy
+60,000
New +$1.84M 0.08% 197

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ESPR Position: Q2 2021 in Review

Weiss Multi-Strategy Advisers sold out of Esperion Therapeutics (ESPR) in Q2 2021, closing a stake of 12,493 shares — an estimated $350K sold.

Weiss Multi-Strategy Advisers first reported a position in ESPR in Q3 2013 and held it in 15 quarters. The position peaked at $2.78M in Q1 2015. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

  • Weiss Multi-Strategy Advisers reported no remaining Esperion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 12,493 Esperion Therapeutics shares in Q2 2021, an estimated $350K.
  • Weiss Multi-Strategy Advisers first reported a position in Esperion Therapeutics in Q3 2013 and held it in 15 quarters.
  • Weiss Multi-Strategy Advisers's Esperion Therapeutics position peaked at $2.78M in Q1 2015.
  • 142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2021, filed 16 Aug 2021.